Nov 27, 2020, 06:30 ET
- On November 19, the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
- On March 31, 2020, the Company entered into an agreement with Tecnologico de Monterrey, the leading university in Mexico, to educate physicians across Latin America, in advance of the impending regulations in Mexico
- To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron's medical education program
- The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico, building on the success of its vertical integration strategy in Colombia
- Expanding the Zerenia clinic strategy will build on the Company's Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
- Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
- Company to release Q3 2020 financials and host webcast on Tuesday, December 1st
TORONTO, Nov. 27, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products. Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.
"We are pleased to see the Mexican legislative and executive branches working together to bring medical cannabis closer to a reality. At Khiron, our goal is to improve the quality of life of 1 million patients by 2024 and Mexico will play an important role in our strategy. Because of this, we partnered with Tecnologico de Monterrey to bring our medical cannabis education platform to doctors working in clinics and health centres across Mexico and LatAm. The clinic model is one we understand well and in which we have proven success. As medical cannabis regulations continue to evolve, we plan to take advantage of our vertical integration model by deploying our Zerenia medical cannabis clinic and telehealth strategy in Mexico," comments Alvaro Torres, Khiron CEO and Director.
Webcast and Q&A
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend a webcast and Q&A to discuss the Company's Q3 2020 financial statements and further activities.
DATE: Tuesday, December 1st, 2020
TIME: 10:00am EST/7:00am PST
PRESENTERS: Alvaro Torres, CEO and Director, Joel Friedman, CFO, and Chris Naprawa, Chairman
FORMAT: Live 30 minutes presentation and Q&A session
REGISTER LINK: https://event.on24.com/wcc/r/2819768/9328DB919FFBB024F2CF5F4F5119285E
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales of medical cannabis.
Leveraging its first-mover advantage and patient-oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
Share this article